Summary of frequency with which trials met their end-points comparing active treatment with placebo or control in each end-point category
| End-point group | Exacerbation-related | Microbiology | Sputum-related | Lung function | HRQoL | Biomarkers (blood and sputum) | Other |
| Primary end-points | 3/7# | 5/5 | 1/4 | 1/4 | 1/5 | 2/4 | 1/2 |
| Accumulative end-points | 9/19 | 6/12 | 5/13 | 3/19 | 9/23¶ | 3/12 | 2/9 |
Data are presented as n/N. HRQoL: health-related quality of life. #: most commonly used primary end-point; ¶: most commonly used end-point (primary and secondary).